Non-Clear Cell RCC: Key Learnings and Future Research Directions

Opinion
Video

The panel discusses key learnings from recent studies in non-clear cell RCC subtypes and the need to better understand disease biology to develop optimized, histology-specific therapies rather than extrapolating clear cell treatment approaches.

CN_ASCO_GU_2024_R360_RCC_Seg09_OUTRO
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      Disease Progression Links to QOL With Cemiplimab/Chemo in Penile Carcinoma
      Disease Progression Links to QOL With Cemiplimab/Chemo in Penile Carcinoma
      Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
      Extending the Benefits of Avelumab Maintenance in Urothelial Carcinoma
      Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
      Predicting Responses to Sacituzumab Govitecan Combo in Urothelial Cancer
      Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
      Exploring The Use of Enfortumab Vedotin in Rare Genitourinary Cancers
      Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
      Determining Personal and Professional Work/Life Balance in GU Oncology
      Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
      Observing the Evolving Prostate Cancer Landscape and Hopes for the Future
      Findings Ways to Embrace Work-Life Balance as a GU Oncologist
      Findings Ways to Embrace Work-Life Balance as a GU Oncologist
      Navigating GU Oncology in a Male-Dominated Field
      Navigating GU Oncology in a Male-Dominated Field
      Frontline Therapy for Patients With Non-Clear Cell RCC
      Frontline Therapy for Patients With Non-Clear Cell RCC
      Related Content
      Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

      Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

      Russ Conroy
      February 21st 2025
      Article

      Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

      Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

      Finding Ways to Break the Mold in GU Oncology

      Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
      April 8th 2024
      Podcast

      Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

      Promising Clinical Activity in UTUC Lesions With Enfortumab Vedotin Plus Pembrolizumab

      Promising Clinical Activity in UTUC Lesions With Enfortumab Vedotin Plus Pembrolizumab

      Jason M. Broderick
      February 14th 2025
      Article

      New data from a small retrospective analysis showed activity with enfortumab vedotin and pembrolizumab in UTUC lesions.

      Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

      Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary Carcinomas

      Matthew Fowler;Quirin Zangl, MD
      November 22nd 2021
      Podcast

      Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

      The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.

      Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer

      Roman Fabbricatore
      August 29th 2024
      Article

      The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.

      Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.

      Frontline Nivolumab Combo Improves TFS Vs Sunitinib in Advanced RCC

      Kyle Doherty
      June 9th 2024
      Article

      Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.